U.S. Releases $600 million to Gavi After Vaccine Safety Dispute Resolved
The Trump administration announced on July 29 that it will immediately unlock $600 million in previously withheld funds for the Gavi vaccine alliance.
On July 29 the Trump administration confirmed the immediate release of $600 million—equivalent to S$773 million—of congressional money earmarked for the Gavi vaccine alliance, ending a hold that stemmed from safety doubts voiced by Health Secretary Robert F. Kennedy Jr. The State Department said the unfreeze was triggered by Gavi’s commitment to transition away from mercury-containing preservatives like thiomersal and to expand access to newer, mercury-free options.
Secretary of State Marco Rubio had earlier called for renewed U.S. involvement with the Geneva-based group, which supplies vaccines to low-income nations. Gavi chief executive Sania Nishtar confirmed the organization is reducing reliance on mercury-based vaccines. The United States, which previously contributed about 13 percent of Gavi’s budget, will reclaim its board seat and will evaluate any further contributions based on demonstrated reforms and accountability. Representatives for Gavi had not responded to a request for comment.
Why it matters
Restoring the funds helps sustain vaccine supplies for the world’s poorest children and signals U.S. re-engagement in global health.
How the sides frame it
MODERATE AGREEMENTLeft-leaning coverage frames the $600 million as a withheld fund pending reforms, while right-leaning coverage presents it as a released amount after safety concerns were resolved.
LEFT
Frames the payment as a punitive withholding that requires reforms before any U.S. money reaches the WHO
RIGHT
Frames the payment as a positive release once vaccine safety disputes were settled
The left emphasises
- withholds $600 million from WHO via Gavi funding cut
- no U.S. money will flow to the World Health Organization
- Trump's instruction to secure reforms before restoring WHO support
The right emphasises
- immediate release of $600 million to Gavi after safety doubts were resolved
- Gavi’s commitment to transition away from mercury-containing preservatives
- renewed U.S. involvement with the vaccine alliance
In this story